Product
BG2109
3 clinical trials
6 indications
Indication
Assisted Reproductive TechnologyIndication
Controlled Ovarian HyperstimulationIndication
EndometriosisIndication
Endometriosis-associated PainIndication
Uterine FibroidsIndication
Heavy menstrual bleedingClinical trial
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of BG2109 in Chinese Subjects With EndometriosisStatus: Recruiting, Estimated PCD: 2024-06-01
Clinical trial
A Randomized, Double-blind, Open for Active Comparator, Parallel, Multi-center Phase II Study to Explore the Efficacy, Safety and Tolerability of BG2109 Compared With Cetrorelix During COH in Female Subjects Undergoing ART ProceduresStatus: Not yet recruiting, Estimated PCD: 2024-06-01
Clinical trial
A Phase 3, Multicentre, Randomized, Double-blind, Placebo-controlled Study Investigating the Efficacy and Safety of Daily Oral Administration of BG2109 Alone and in Combination With Add-back Therapy for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women.Status: Recruiting, Estimated PCD: 2024-05-01